Chagas: Time to Treat campaign

Last updated
Logo Logo treat chagas.jpg
Logo

The Chagas: Time to Treat Campaign is an international campaign started by the Drugs for Neglected Diseases initiative to advocate for increased research and development of treatments for Chagas disease. Chagas is a potentially fatal neglected disease that affects between 8 and 13 million people worldwide. DNDi's Time to Treat campaign is pushing for increased political interest in new treatments for Chagas disease, increased public awareness of the disease and treatment limitations and increased public and private investment in R&D.

Contents

The disease

Each year over 8 million people in the Americas contract the Chagas disease. Chagas occurs in two stages and kills more people in the region than any other parasite-borne disease, including malaria. It is caused by the parasite Trypanosoma cruzi transmitted primarily by insects known as "kissing bugs". The existing treatments are not satisfactory and can have toxic side effects. What patients urgently need are affordable, safe, and efficacious diagnostics tools and treatments for children and adults as well as a drug that treats both stages of Chagas. [1] [2]

Current treatments

Current drugs are limited to the treatment of children under the age of 12 years who are in the acute stages and the chronic asymptomatic stages. Treatments for Chagas disease are not curative once patients have begun experiencing complications in the chronic stages. [3] [4] [5] In addition to the limitations of the effectiveness of the treatments, the available drugs are expensive, have extensive side effect profiles and have a long treatment course which can be difficult to follow. It has been estimated that no more than 1% of Chagas disease patients receive any treatment at all. [6]

R&D funding

Increased public and private funding for R&D into Chagas treatments is needed. Given the 100 million people at risk and Chagas disease's disease burden, funding for R&D to improve treatments is extremely low, making it one of the most neglected of the neglected diseases. In 2007, less than US$1 million (0.04% of R&D funding dedicated to neglected diseases) was spent on the development of new drugs for Chagas disease. [7] [8]

Treatment needs

DNDi's Chagas: Time to Treat campaign is advocating for the following treatment options for all stages of Chagas infection:[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Chagas disease</span> Mammal parasitic disease

Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by Trypanosoma cruzi. It is spread mostly by insects in the subfamily Triatominae, known as "kissing bugs". The symptoms change over the course of the infection. In the early stage, symptoms are typically either not present or mild, and may include fever, swollen lymph nodes, headaches, or swelling at the site of the bite. After four to eight weeks, untreated individuals enter the chronic phase of disease, which in most cases does not result in further symptoms. Up to 45% of people with chronic infections develop heart disease 10–30 years after the initial illness, which can lead to heart failure. Digestive complications, including an enlarged esophagus or an enlarged colon, may also occur in up to 21% of people, and up to 10% of people may experience nerve damage.

<span class="mw-page-title-main">African trypanosomiasis</span> Parasitic disease also known as sleeping sickness

African trypanosomiasis, also known as African sleeping sickness or simply sleeping sickness, is an insect-borne parasitic infection of humans and other animals. It is caused by the species Trypanosoma brucei. Humans are infected by two types, Trypanosoma brucei gambiense (TbG) and Trypanosoma brucei rhodesiense (TbR). TbG causes over 92% of reported cases. Both are usually transmitted by the bite of an infected tsetse fly and are most common in rural areas.

<span class="mw-page-title-main">Trypanosomiasis</span> Medical condition

Trypanosomiasis or trypanosomosis is the name of several diseases in vertebrates caused by parasitic protozoan trypanosomes of the genus Trypanosoma. In humans this includes African trypanosomiasis and Chagas disease. A number of other diseases occur in other animals.

<i>Trypanosoma</i> Genus of parasitic flagellate protist in the Kinetoplastea class

Trypanosoma is a genus of kinetoplastids, a monophyletic group of unicellular parasitic flagellate protozoa. Trypanosoma is part of the phylum Sarcomastigophora. The name is derived from the Greek trypano- (borer) and soma (body) because of their corkscrew-like motion. Most trypanosomes are heteroxenous and most are transmitted via a vector. The majority of species are transmitted by blood-feeding invertebrates, but there are different mechanisms among the varying species. Some, such as Trypanosoma equiperdum, are spread by direct contact. In an invertebrate host they are generally found in the intestine, but normally occupy the bloodstream or an intracellular environment in the vertebrate host.

<span class="mw-page-title-main">Carlos Chagas</span> Brazilian doctor and scientist (1879–1934)

Carlos Justiniano Ribeiro Chagas, or Carlos Chagas, was a Brazilian sanitary physician, scientist, and microbiologist who worked as a clinician and researcher. Most well known for the discovery of an eponymous protozoal infection called Chagas disease, also called American trypanosomiasis, he also discovered the causative fungi of the pneumocystis pneumonia. He described the two pathogens in 1909, while he was working at the Oswaldo Cruz Institute in Rio de Janeiro, and named the former Trypanosoma cruzi to honour his friend Oswaldo Cruz.

<span class="mw-page-title-main">Megacolon</span> Medical condition

Megacolon is an abnormal dilation of the colon. This leads to hypertrophy of the colon. The dilation is often accompanied by a paralysis of the peristaltic movements of the bowel. In more extreme cases, the feces consolidate into hard masses inside the colon, called fecalomas, which can require surgery to be removed.

<i>Panstrongylus geniculatus</i> Species of true bug

Panstrogylus geniculatus is a blood-sucking sylvatic insect noted as a putative vector of minor importance in the transmission of Trypanosoma cruzi to humans; this is a parasite, which causes Chagas disease. The insect is described as sylvatic; subsisting primarily in humid forests, and is also known to inhabit vertebrate nesting places such as those of the armadillo, and is also involved in enzootic transmission of T. cruzi to those species. It has wide distribution throughout 16 Latin American countries.

Alkhurma virus (ALKV) is a zoonotic virus of the Flaviviridae virus family. ALKV causes Alkhurma hemorrhagic fever (AHF), or alternatively termed as Alkhurma hemorrhagic fever virus, and is mainly based in Saudi Arabia.

<i>Trypanosoma cruzi</i> Species of parasitic euglenoids (protozoans)

Trypanosoma cruzi is a species of parasitic euglenoids. Among the protozoa, the trypanosomes characteristically bore tissue in another organism and feed on blood (primarily) and also lymph. This behaviour causes disease or the likelihood of disease that varies with the organism: Chagas disease in humans, dourine and surra in horses, and a brucellosis-like disease in cattle. Parasites need a host body and the haematophagous insect triatomine is the major vector in accord with a mechanism of infection. The triatomine likes the nests of vertebrate animals for shelter, where it bites and sucks blood for food. Individual triatomines infected with protozoa from other contact with animals transmit trypanosomes when the triatomine deposits its faeces on the host's skin surface and then bites. Penetration of the infected faeces is further facilitated by the scratching of the bite area by the human or animal host.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Neglected tropical diseases</span> Diverse group of tropical infectious diseases which are common in developing countries

Neglected tropical diseases (NTDs) are a diverse group of tropical infections that are common in low-income populations in developing regions of Africa, Asia, and the Americas. They are caused by a variety of pathogens, such as viruses, bacteria, protozoa, and parasitic worms (helminths). These diseases are contrasted with the "big three" infectious diseases, which generally receive greater treatment and research funding. In sub-Saharan Africa, the effect of neglected tropical diseases as a group is comparable to that of malaria and tuberculosis. NTD co-infection can also make HIV/AIDS and tuberculosis more deadly.

<span class="mw-page-title-main">Benznidazole</span> Chemical compound

Benznidazole is an antiparasitic medication used in the treatment of Chagas disease. While it is highly effective in early disease, the effectiveness decreases in those who have long-term infection. It is the first-line treatment given its moderate side effects compared to nifurtimox. It is taken by mouth.

<span class="mw-page-title-main">Nifurtimox</span> Anti-parasitic medical drug

Nifurtimox, sold under the brand name Lampit, is a medication used to treat Chagas disease and sleeping sickness. For sleeping sickness it is used together with eflornithine in nifurtimox-eflornithine combination treatment. In Chagas disease it is a second-line option to benznidazole. It is given by mouth.

Trypanosoma rangeli is a species of hemoflagellate excavate parasites of the genus Trypanosoma. Although infecting a variety of mammalian species in a wide geographical area in Central and South America, this parasite is considered non-pathogenic to these hosts. T. rangeli is transmitted by bite of infected triatomine bugs of the Reduviidae family, commonly known as barbeiro, winchuka(vinchuca), chinche, pito ou chupão.

Cruzipain is a cysteine protease expressed by Trypanosoma cruzi.

Fexinidazole is a medication used to treat African trypanosomiasis caused by Trypanosoma brucei gambiense. It is effective against both first and second stage disease. Also a potential new treatment for Chagas disease, a neglected tropical disease that affects millions of people worldwide. It is taken by mouth.

<span class="mw-page-title-main">VNI (molecule)</span> Chemical compound

VNI is an experimental drug for treating Chagas disease currently being studied at Vanderbilt University. The molecule acts by inhibiting Trypanosoma cruzi sterol 14α-desmethylase activity in vitro. It exhibits no toxicity in mouse cells and unlike the related compounds posaconazole and fluconazole, increasing the dose is not required to maintain anti-parasitic activity.

Mundo Sano, or Fundación Mundo Sano, is a scientific, nongovernmental foundation in Argentina working for the prevention and control of communicable diseases such as dengue fever, Chagas disease, malaria, leishmaniasis and soil-transmitted helminthiasis. Its main objective is to facilitate equal access to health and welfare among people who are vulnerable to these otherwise avoidable diseases, mainly by promoting strategic policies for the improvement of the quality of life of affected communities.

<span class="mw-page-title-main">Acoziborole</span> Antiprotozoal drug to treat sleeping sickness

Acoziborole (SCYX-7158) is an antiprotozoal drug invented by Anacor Pharmaceuticals in 2009, and now under development by the Drugs for Neglected Diseases Initiative for the treatment of African trypanosomiasis.

Neglected tropical diseases in India are a group of bacterial, parasitic, viral, and fungal infections that are common in low income countries but receive little funding to address them. Neglected tropical diseases are common in India.

References

  1. Médecins Sans Frontières. Campaign for Access to Essential Medicines (2008). "International meeting: new diagnostic tests are urgently needed to treat patients with Chagas disease". Revista Da Sociedade Brasileira De Medicina Tropical. 41 (3): 315–319. doi: 10.1590/s0037-86822008000300020 . ISSN   0037-8682. PMID   18719818.
  2. Chatelain, Eric (2015-01-01). "Chagas Disease Drug Discovery: Toward a New Era". SLAS Discovery. Special Issue: Novel Therapeutic Approaches for Neglected Infectious Diseases. Full and immediate open access to all manuscripts published in this special issue is courtesy of the Drugs for Neglected Diseases Initiative (DNDi). 20 (1): 22–35. doi: 10.1177/1087057114550585 . ISSN   2472-5552.
  3. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, et al. (2007) Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298: 2171–2181.
  4. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, et al. (1996) Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407–1413
  5. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, et al. (1998) Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 59: 526–529.
  6. Ribeiro I, Sevcsik A-M, Alves F, Diap G, Don R, et al. 2009 New, Improved Treatments for Chagas Disease: From the R&D Pipeline to the Patients. PLoS Negl Trop Dis 3(7): e484. doi : 10.1371/journal.pntd.0000484
  7. Moran M, Guzman J, Ropars AL, McDonald A, Jameson N, et al. (2009) Neglected disease research and development: how much are we really spending? PLoS Med 6: e30. doi : 10.1371/journal.pmed.1000030
  8. Ribeiro I, Sevcsik A-M, Alves F, Diap G, Don R, et al. 2009 New, Improved Treatments for Chagas Disease: From the R&D Pipeline to the Patients. PLoS Negl Trop Dis 3(7): e484. doi : 10.1371/journal.pntd.0000484 [http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000030
  9. "Global View". Archived from the original on 2009-09-12. Retrieved 2009-08-03.